19 results about "Optic nerve" patented technology

The invention relates to application of graphene-(RADA-IKVAV)-pranoprofen, eye drops and a preparation method of the eye drops. The invention relates to graphene-(RADA-IKVAV)-pranoprofen, the graphene-(RADA-IKVAV)-pranoprofen comprises graphene-polyacrylic acid, self-assembled oligopeptide RADA-IKVAV and pranoprofen, the self-assembled oligopeptide RADA-IKVAV is connected with the graphene-polyacrylic acid through a chemical bond, and the pranoprofen is loaded on the surface of the graphene-polyacrylic acid. The eye drops provided by the invention comprise graphene-(RADA-IKVAV)-pranoprofen, so that the drug loading capacity of pranoprofen in the eye drops is increased, the bioavailability of drugs is improved, and the eye drops are used for inhibiting eye inflammation; the coupled oligopeptide RADA-IKVAV simulates an extracellular environment, provides a suitable microenvironment for eyes, promotes nerve repair and regeneration by influencing nerve growth factors, and promotes optic nerve repair.

This invention belongs to the field of animal model technology and discloses a method and system for constructing a NMOSD mouse model. The method includes extracting NMO-IgG from patient plasma replacement fluid, actively immunizing mice with an AQP4 p201-220 peptide emulsion, and injecting NMO-IgG to establish an NMOSD animal model. This invention uses active immunization with AQP4 p201-220 peptide combined with an antigen adjuvant, and then injects patient-derived NMO-IgG on this basis. Compared with other existing animal models, the characteristic clinical manifestations of NMOSD, including the detection of peripheral blood AQP4-IgG autoantibodies and the characteristic loss of AQP4 and GFAP proteins in the retina, optic nerve, and spinal cord, are more significant, more objectively reflecting the disease characteristics of NMOSD and providing a new research platform for related studies.

This invention belongs to the field of biomedical technology, specifically relating to an engineered exosome and its applications. This invention is the first to discover that PCDH12 is specifically highly expressed in the trabecular meshwork tissue of glaucoma patients. Based on this target, engineered exosomes loaded with PCDH12 antibodies were successfully developed. These engineered exosomes can achieve non-invasive and precise targeted delivery to the trabecular meshwork tissue. In glaucoma model mouse experiments, they not only significantly reduced intraocular pressure but also effectively protected the optic nerve. The non-invasive and precise delivery strategy proposed in this invention combines potent intraocular pressure reduction with direct neuroprotection, providing a candidate solution with direct clinical translational potential for integrated "pressure reduction-neuroprotection" treatment of glaucoma.

The application relates to an artificial visual nervous system based on a bimodal neural device, comprising a bimodal visual information calculation array composed of a physical convolution kernel array and a synapse calculation array, the physical convolution kernel array is used for receiving an ambient light signal and converting into an electrical signal output, the synapse calculation array is used for receiving the electrical signal and converting into a visual signal, and the physical convolution kernel array and the synapse calculation array are both composed of a plurality of bimodal transistors. The application has excellent bimodal collaborative calculation capability, the receptive field mechanism (excitatory / inhibitory response) of a retinal bipolar cell is simulated through the physical convolution kernel array, image feature extraction and preprocessing are realized, the synaptic plasticity (LTP / LTD mechanism) of a central nervous system is simulated in combination with the synapse calculation array, high-level calculation of the visual signal is completed, and a complete visual nerve bionic system is formed by virtue of an array composed of single devices.

The present invention pertains to an optical nerve protecting agent containing an anti-low density lipoprotein receptor-related protein 1 (LRP1) antibody or fragment of the anti-LRP1 antibody.

This invention discloses an injectable hydrogel for long-term sustained release of NGF and CNTF, its preparation method, and its application in visual system diseases. The bioactive factor sustained-release hydrogel of this invention comprises a hydrogel matrix and bioactive factor microspheres loaded on the matrix; the raw materials for preparing the hydrogel matrix include chitosan, type II collagen, and hyaluronic acid; the bioactive factor microspheres comprise an inner core and a capsule wall, the inner core being a bioactive factor selected from one or both of ciliary neurotrophic factor and nerve growth factor, and the capsule wall being a polylactic acid-glycolic acid copolymer. This hydrogel can achieve long-term stable release of NTF, activating endogenous neural stem cells in the retina to generate new retinal ganglion cells. It exhibits high safety, good injectability, and a long sustained-release period, and can be used to prepare drugs for treating visual system diseases such as glaucoma, optic nerve damage, and macular degeneration.

An N-(4-trifluoromethyl)-2-cyanocrotonamide compound, a preparation method therefor, and a pharmaceutical composition and use thereof. The compound of the present invention has a more significant treatment effect on central nervous system diseases such as multiple sclerosis and neuromyelitis optica.

The application discloses application of an S1PR1 selective agonist SAR247799 in preparation of a drug for treating neuromyelitis optica spectrum disorders. The SAR247799 can up-regulate S1PR1 expression of astrocytes, activate an S1PR1 signal path of the astrocytes, inhibit AQP4-IgG and complement-mediated damage of the astrocytes, reduce loss of AQP4, GFAP and ALDH1L1 in a lesion area of brain tissue of a neuromyelitis optica spectrum disorder model mouse, and relieve pathological damage of the neuromyelitis optica spectrum disorder model. In-vivo and in-vitro experiments prove that the SAR247799 can effectively inhibit AQP4-IgG and complement-dependent cytotoxicity effects and promote survival of the astrocytes. The application provides a novel, efficient and specific targeted drug for clinical treatment of the neuromyelitis optica spectrum disorder.

FIELD: ophthalmology.SUBSTANCE: used for objective differential diagnostics of the anatomical form of the optic nerve disc (OND) deepening. Optical coherence tomography is performed on the Optovue RTVue XR Avanti System using the 3D Disc program. Images of the optic disc are obtained in the horizontal plane, a straight line is drawn between the visible boundaries of the retinal pigment epithelium (RPE) and the position and shape of the bottom of the OND deepening are assessed. When the depression is at the level of the RPE and the angle of its bottom is less than or equal to 90° a triangular shape is defined. If the depression is located above the RPE level and the angle of its bottom is more than 90° a flat shape is defined. If the depression is below the RPE level and the bottom angle is less than or equal to 90° a wedge shape is defined. If the depression is below the RPE level, and its bottom forms a base and two angles, a trapezoidal shape is defined.EFFECT: improving the accuracy, objectivity and reproducibility of determining the individual anatomical shape of the OND excavation by using a stable anatomical landmark – the RPE and standardized geometric parameters, which eliminates subjective error in diagnosis.1 cl, 7 dwg, 1 tbl, 3 ex

The present invention relates to an AI-based image processing device for segmenting an optic nerve structure to diagnose a visual abnormality. The AI-based image processing device for segmenting an optic nerve structure to diagnose a visual abnormality according to an aspect of the present invention comprises: a first encoder including a convolution block and multiple layer blocks and for calculating multi-level features from an RGB image obtained by photographing eyes; a second encoder for performing a multi-head self-attention operation on a top-level feature output from the first encoder, and applying same to a multi-layer perceptron to calculate a feature obtained by capturing spatial dimension dependency; and a decoder for: obtaining an image in which spatial features are emphasized, by repeating a process of connecting, to a result obtained by performing an attention operation on each feature remaining after excluding the top-level feature from among the multi-level features output from the first encoder and up-sampling the feature output from the second encoder, a result obtained by performing an attention operation on each feature from the upper level, performing a convolution operation, up-sampling same, and then connecting a result obtained by performing an attention operation on the next lower-level feature; and segmenting regions corresponding to an optic nerve disk and an optic nerve cup, respectively.

This invention discloses a longitudinal section positioning device for frozen sections of the optic nerve and its method of use. The positioning device includes: a stage having a platform slope, on which a fixing plate and a fixing groove are formed, the fixing groove being located at the upper end of the platform slope and the fixing plate being located at the lower end of the platform slope, wherein the fixing plate is used to support the eyeball and the fixing groove is used to place the nerve; an optic nerve clamp being movably and adjustablely disposed within the fixing groove along the extension direction of the fixing groove, used to clamp the tail end of the nerve and adjust the state of the eyeball on the platform slope; and a side plate assembly connected in the circumferential direction of the stage, the side plate assembly being configured to switch between an open position and a closed position of the stage; wherein the side plate assembly has a notch communicating with the fixing groove, and when the side plate assembly is in the closed position, it forms a receiving cavity with an open end above the platform slope.

The invention relates to a device (102) for determining the gaze direction of an eye for data glasses (100), wherein the device (102) comprises a laser device (108) configured to emit a first beam for illuminating the optic nerve of the eye and to determine a first position of a first image of a first reflection beam representing a first reflection of the first beam at the optic nerve, and to determine a second position of a second image of a second reflection beam representing a second reflection from an area of ​​the retina of the eye differing from the optic nerve, and a detection device (110) configured to determine the gaze direction using the first position and the second position.

A device for relieving dementia symptoms is disclosed. The device for relieving dementia symptoms includes a light stimulation part disposed at a location within a preset radius from an eyeball and frontal lobe of a patient and configured to relieve dementia symptoms of the patient by radiating light having a preset wavelength band to an optic nerve and frontal lobe of the patient, and a central processing unit configured to control an operation of the light stimulation part.

This invention discloses the application of BHLHE40 in the preparation of prognostic assessment kits and therapeutic drugs for retinoblastoma. Through a series of in vitro and in vivo experiments, this invention demonstrates that knocking down BHLHE40 expression significantly inhibits the proliferation of retinoblastoma cells, exhibiting a significant tumor-suppressive effect. Therefore, it is proposed that BHLHE40 inhibitors can be used in the preparation of therapeutic drugs for retinoblastoma, providing a new, effective, and safe treatment option for RB patients. Furthermore, BHLHE40 can serve as a drug target to guide subsequent drug development. In addition, this invention also utilizes clinical tumor tissue samples to demonstrate that high BHLHE40 expression is significantly positively correlated with high-risk pathological features such as optic nerve invasion, scleral invasion, and choroidal invasion, suggesting that BHLHE40 can serve as an effective biomarker for predicting high-risk pathological features, assisting physicians in treatment decisions.

The present invention relates to Nerve growth factor (NGF) or a mutein thereof for use in the prevention or treatment of a retinopathy or of an optic nerve disorder in a subject, wherein said NGF is administered intranasally to the subject.

The embodiment of the application discloses a magnetic resonance receiving device, which is suitable for optic nerve imaging of a goat. The magnetic resonance receiving device comprises a shell, a plurality of receiving coils and a receiving circuit. The shell has a containing cavity for containing the head of the goat, and the shell can be matched with the contour of the head of the goat. The plurality of receiving coils are arranged in the shell. The receiving circuit is arranged in the shell and is electrically connected with each receiving coil and is used for connecting an external device. When the shell is arranged on the head of the goat, the plurality of receiving coils are used for receiving the radio frequency signal of the optic nerve of the goat, so that the external device can obtain the optic nerve image of the goat, and the accuracy of the optic nerve image of the goat obtained by the external device is improved. In addition, the plurality of receiving coils can be matched with the contour of the head of the goat, and the efficiency of the radio frequency signal received by each receiving coil is also improved, so that the efficiency of the optic nerve image of the goat obtained by the external device through the magnetic resonance receiving device is improved.

The application discloses a compound for eye disease repair and a preparation method of the compound by aging extraction, which is synthesized by extracting effective components of Senecio scandens Buch, astaxanthin, Artemisia capillaris Thunb, Gardenia, Ceti, Cassia seed, and has good therapeutic effect on eye diseases such as myopia, pseudomyopia, cataract, glaucoma, chloasma and the like. By taking the extract, intraocular pressure, optic nerve and intraocular pressure tube are gradually improved, so that the eye axis refraction is basically recovered, and the purpose of basic cure is achieved. The extract is obtained by supercritical extraction of pure plants and traditional Chinese medicines, and the compound Tianmocai compound of Senecio scandens Buch is obtained by using three reaction kettles to induce aging technology, the compound is safe and has no side effect, and is an innovative modern new Chinese medicine technical product.

This invention discloses an exosome-like nanovesicle derived from Hangzhou white chrysanthemum, its preparation method, and its application in the treatment of optic nerve and retinal degenerative diseases. In vitro experiments show that the exosome-like nanovesicles derived from Hangzhou white chrysanthemum provided by this invention can effectively inhibit glutamate-induced oxidative stress and mitochondrial damage in retinal cells, and enhance cell viability. In vivo experiments show that intravitreal injection of these exosome-like nanovesicles derived from Hangzhou white chrysanthemum can significantly improve the survival rate of ganglion cells in the retina of mice with NMDA damage and improve their visual electrophysiological function. This invention provides a new approach and method for the treatment of optic nerve and retinal degenerative diseases, and has broad application prospects. Furthermore, the preparation method of the exosome-like nanovesicles derived from Hangzhou white chrysanthemum provided by this invention is simple and has advantages such as low cost, wide applicability, good safety, and absence of animal-derived components.

Disclosed herein are methods of treating autoimmune diseases using anti-CD19 antibodies. In particular, VIB551, a humanized, affinity-optimized, afucosylated IgG1 kappa monoclonal antibody, is used to treat neuromyelitis optica spectrum disorders.